Nicolet Bankshares Form 144 Shows 1,564-Share Sale After Option Exercise
Rhea-AI Filing Summary
Nicolet Bankshares (NIC) Form 144 notice: An individual proposes to sell 1,564 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $213,793.50, scheduled approximately for 08/26/2025. The shares were acquired on 08/26/2025 by stock option exercise from the issuer, and payment was made in cash on that date. The filing discloses one prior sale in the past three months: 5,000 common shares sold on 07/18/2025 for $698,864.50 by Eric Witczak. The filer certifies they are unaware of any undisclosed material adverse information about the issuer and provides the standard legal attestation regarding accuracy of the notice.
Positive
- Timely disclosure of proposed insider sale through a live Form 144 filing
- Complete transactional details provided: acquisition method, broker, exchange, number of shares, and aggregate market value
- Standard attestation included confirming no undisclosed material adverse information
Negative
- Insider selling activity includes a prior sale of 5,000 shares within the past three months, which may warrant investor attention
Insights
TL;DR: Routine insider notice of sale following option exercise; limited market impact shown by disclosed sizes.
The Form 144 documents a proposed sale of 1,564 shares acquired via stock option exercise and a prior sale of 5,000 shares within three months. The notice follows Rule 144 procedures by identifying broker, exchange, acquisition method, and gross proceeds for the recent sale. For investors, this is a disclosure of insider liquidity activity rather than a corporate operational event; it permits market participants to assess insider selling cadence. No earnings or corporate governance changes are disclosed in this filing.
TL;DR: Filing demonstrates compliance with disclosure rules; includes required attestation about material undisclosed information.
The filer provides requisite details: acquisition date, nature of acquisition (stock option exercise), broker identity, planned sale date, and aggregate market value. The signature attestation that no undisclosed material adverse information exists is present, which is standard and important for regulatory compliance. The submission appears procedural and does not announce corporate governance actions or changes in management.